Key Developments: Merck & Co Inc (MRK)

MRK on New York Consolidated

57.67USD
2 Jul 2015
Change (% chg)

$0.07 (+0.12%)
Prev Close
$57.60
Open
$57.94
Day's High
$58.33
Day's Low
$57.50
Volume
8,518,380
Avg. Vol
10,592,908
52-wk High
$63.62
52-wk Low
$52.49

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck announces phase 3 study of single-dose EMEND
Monday, 29 Jun 2015 08:30am EDT 

Merck:Says results from a Phase 3 study investigating safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Merck's substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines.Says for prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC).Says plans to submit these recent data to the food and drug administration in the second half of 2015.  Full Article

Merck & Co Inc Cardiovascular safety trial of Januvia (Sitagliptin), met primary endpoint in patients with type 2 diabetes
Wednesday, 10 Jun 2015 07:00am EDT 

Merck & Co Inc:Cardiovascular safety trial of Januvia (Sitagliptin), met primary endpoint in patients with type 2 diabetes.Says treatment with sitagliptin did not increase the risk of major adverse cardiovascular events in the primary composite endpoint.Says there was no increase in hospitalization for heart failure, and rates of all-cause mortality were similar in both treatment groups.  Full Article

Merck & Co Inc's Keytruda (pembrolizumab) receives conditional approval in Canada for treatment of Advanced Melanoma
Monday, 8 Jun 2015 07:00am EDT 

Merck & Co Inc:Merck's Keytruda (pembrolizumab) receives conditional approval in Canada for the treatment of Advanced Melanoma.Says Keytruda (pembrolizumab) was authorized for sale with conditions by health Canada on May 19.  Full Article

Merck & Co Inc announces results from investigational IMPROVE-IT Study of VYTORIN published in New England Journal of Medicine
Wednesday, 3 Jun 2015 05:00pm EDT 

Merck & Co Inc:Says safety findings from improve-it were generally consistent with current labeling for ezetimibe.  Full Article

Merck & Co Inc and Dynavax Technologies Corp announce new collaboration investigating combination of Immuno-Oncology Therapies
Monday, 1 Jun 2015 08:30am EDT 

Merck & Co Inc and Dynavax Technologies Corp:Say new collaboration investigating combination of Immuno-Oncology Therapies.DYNAVAX will sponsor and fund the SD-101 and Keytruda Study.Merck will sponsor and fund the SD-101 and MK-1966 Study.Says agreements include provisions where the parties may agree to extend either collaboration to include a phase 3 clinical trial.Additional details of the agreements between Dynavax and Merck, through a subsidiary, were not disclosed.  Full Article

Amgen And Merck Announce Expansion Of Collaboration
Friday, 29 May 2015 08:30am EDT 

Merck:Amgen and Merck announce expansion of collaboration to support studies of talimogene laherparepvec in combination with keytruda (pembrolizumab) in patients with head and neck cancer.Says companies also plan to initiate phase 3 trial in combination for advanced melanoma.Merck- companies say that phase 3 trial evaluating combination in patients with regionally or distantly metastatic melanoma being initiated.  Full Article

Merck submits U.S. New Drug Application for Grazoprevir/Elbasvir
Thursday, 28 May 2015 04:30pm EDT 

Merck & Co Inc:Submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection.  Full Article

Merck and NanoString Announce Clinical Research Collaboration
Thursday, 28 May 2015 08:30am EDT 

Merck and NanoString:Says clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck's anti-PD-1 therapy, KEYTRUDA(pembrolizumab) in multiple tumor types.Says collaboration between NanoString Technologies, Inc., and Merck, through a subsidiary, will utilize NanoString's nCounter Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA.  Full Article

Merck & Co Inc announces Q3 2015 Dividend
Tuesday, 26 May 2015 01:31pm EDT 

Merck & Co Inc:Declares quarterly dividend of $0.45 per share.Payable on July 8, to stockholders of record at close of business on June 15.  Full Article

Merck & Co., Inc receives positive CHMP opinion for Pembrolizumab for treatment of advanced melanoma
Friday, 22 May 2015 07:12am EDT 

Merck & Co., Inc:Says Committee for Medicinal Products for Human Use of European Medicines Agency has adopted positive opinion recommending approval of pembrolizumab, co's anti-PD-1 therapy for the treatment of advanced melanoma as both first-line therapy and in previously-treated patients.CHMP positive opinion for pembrolizumab, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union (EU).  Full Article

UPDATE 1-Merck aims to be leader in OLED materials by 2018

* Merck is market leader in liquid crystals (Adds details on competitors, investment)

Search Stocks